微生物菌群与抗肿瘤药物疗效及不良反应相关性研究进展

Research Progress on the Correlation Between Microbiota and the Efficacy and Adverse Reactions of Antitumor Drug

抗肿瘤药物不断推陈出新,但药物响应率有限及药物不良反应问题严重限制了其临床应用。近年来,“药物微生物组学”概念兴起,越来越多的研究表明,人体微生物菌群在抗肿瘤药物治疗中发挥重要作用。本文从化疗药物、分子靶向药物、免疫治疗药物三方面综述微生物菌群与抗肿瘤药物的相互作用,机制涉及免疫调节、激素水平调节、代谢物水平调节、药物生物转化及跨膜转运调节等,并对可改善抗肿瘤药物疗效及不良反应的微生物菌群调控策略进行概述,以期为临床抗肿瘤药物个体化治疗提供参考。

Despite the rapid development of antitumor drugs, the limited drug response rate and adverse drug reactions have severely limited their clinical application. In recent years, the concept of “pharmacomicrobiomics” has emerged, and more and more studies have shown that microbiota plays an important role in the treatment of antitumor drugs. Herein, the interaction between microbiota and antitumor drugs is reviewed from the aspects of chemotherapeutics, molecular targeted drugs and immunotherapy drugs. The mechanism involves immune regulation, hormone regulation, metabolite regulation, drug biotransformation and transmembrane transport regulation. The microbiota regulation strategies that can improve the efficacy and reduce adverse reactions of antitumor drugs are reviewed, in order to provide reference for the individualized treatment of clinical antitumor drugs.